Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients.

DISCUSSION: Anti-PD-1/anti-PD-L1 re-challenge showed interesting clinical activity in selected patients, mainly in those achieving a long-term response upon the first ICPi course, that do not discontinue therapy because of disease progression, or that are able to keep a treatment-free period.
PMID: 33032816 [PubMed - as supplied by publisher]

Source: Bulletin du Cancer - October 5, 2020 Category: Cancer & Oncology Authors: Gobbini E, Charles J, Toffart AC, Leccia MT, Moro-Sibilot D, Levra MG Tags: Bull Cancer Source Type: research